Soliqua

Before taking this medicine

Do not use Soliqua during an episode of low blood sugar or if you have had a serious allergic reaction to insulin glargine, lixisenatide or any other ingredient. Stop use and seek medical attention promptly if a severe allergic reaction occurs. Soliqua is not recommended for people with end-stage kidney disease or severe gastroparesis (severely delayed stomach emptying). Do not use it with another GLP-1 receptor agonist. During pregnancy, it should be used only if the potential benefit justifies the potential risk to the fetus. Close medical supervision and more frequent blood sugar checks are needed when changing an insulin regimen. Extra monitoring may also be needed with changes in other blood sugar-lowering medicines, meals or physical activity, or if you have kidney or liver problems or do not notice the warning signs of low blood sugar. Low blood sugar can be life-threatening. Other important risks include pancreatitis, severe digestive side effects, dehydration-related kidney injury, low blood potassium and gallbladder disease. Stop Soliqua if pancreatitis is suspected. Using it with PPAR-gamma agonists can cause fluid retention and heart failure. Worsening blood sugar control, significant injection-site reactions or allergic reactions may require a change in treatment. Tell your healthcare team about any planned surgery or procedure involving general anesthesia or deep sedation, because stomach contents may enter the lungs. Never share the pen, even if the needle is changed, and check the medicine label before every injection to avoid medication errors.